Logo 1 Logo 2

Therapeutic Strategy Details

Strategy ID: S06
Strategy: anti-platelet aggregation
Other Terms: Percutaneous left atrial appendage occlusion (LAAO); Antiplatelet therapy; Anti-platelet aggregation; antiplatelet therapy; Anti-hypertensive; Anti-platelet aggregation; Anti-platelet aggregation; Enhance lipid metabolism; platelet-rich plasma injections (PRP); Antiplatelet treatment; Anti-hypertensive; Enhance lipid metabolism; Anti-platelet aggregation; Enhance lipid metabolism; Anti-platelet aggregation
Related Targets:
Related Drugs: oral anticoagulation; antiplatelet therapy; clopidogrel; OAC therapy; antiplatelet therapy; ticagrelor; aspirin; antiplatelet therapy; beraprost; cinacalcet; lanthanum carbonate; Amiodarone; Ticagrelor; Clopidogrel; antithrombotic agents; single antiplatelet therapy; dual antiplatelet; anticoagulation and antiplatelet; anticoagulation monotherapy; antihypertensive agents; antithrombotics; antianemics; proton pump inhibitors; allopurinol; rilmenidine; long-term benzodiazepines; anticholinergic drugs; hydroxyzine; insulin; dual antiplatelet therapy; statins; beta-blockers; prasugrel; clopidogrel; aspirin; non-steroid antiinflamatory drugs; platelet-rich plasma injections; warfarin; direct acting oral anticoagulant; bivalirudin; DOACs; warfarin; APT; antithrombotic therapy; antithrombotic agents; antiplatelet therapy; captopril; tiopronin; active form of dalcetrapib; active metabolite of prasugrel, R-138727; aspirin; clopidogrel; prasugrel; ticagrelor; rivaroxaban; statins
Mechanism:
Reference (PMIDs): 31715006; 31721430; 31872246; 31925529; 31977867; 32056163; 32057375; 32126388; 32131742; 32162781; 32239221; 32297967; 32408815; 32492401; 32556819; 32611318; 32744915; 32811401; 32969145; 33066794